1 July 2023 in Clinical, Cosmetic and Investigational Dermatology
Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition that can progress to significant tunnels and scars that affect quality of life, especially if diagnosis and treatment are delayed. Average delay after initial presentation of HS symptoms can range from 3 to 10 years in adults and 1 to 2 years in children. Factors associated with diagnostic delay include female gender, non-white race, and greater disease severity at diagnosis. Contributing factors include misdiagnoses, difficulty accessing a dermatologist, hesitation in seeking care due to the stigmatizing nature of the disease, and lack of awareness among providers and patients. While efforts to increase awareness include academic talks at conferences and by foundations geared toward HS, social media offers the opportunity to reach young audiences. Many patients report dissatisfaction with their HS treatments. Better understanding of HS pathophysiology and implementation of clinically focused phenotypes and endotypes can lead to development of more targeted and efficacious therapies. FDA approval of medications for HS beyond adalimumab will increase access to a wider selection of therapies, and implementation of therapeutic drug monitoring may maximize the use of biologics for HS.
16 October 2023 in Immunotherapy
The IL-17 pathways are involved in the pathophysiology of many inflammatory skin conditions, including hidradenitis suppurativa. Secukinumab, an IL-17A inhibitor, has been used for years in inflamm... Plain language summary Hidradenitis suppurativa is a chronic skin disorder characterized by recurrent painful bumps, tunnels underneath the skin and significant scarring. To date, the only US FDA-a... Tweetable abstract Secukinumab, an IL-17A inhibitor, has been used for years in inflammatory skin disorders such as psoriasis. We review its role in the treatment of hidradenitis suppurativa (HS).
12 September 2025 in British Journal of Dermatology
HS-KAPPA, an accessible hidradenitis suppurativa (HS) phenotype algorithm, was developed to reliably categorize patients with HS based on morphology. We validated HS-KAPPA with a reproducible training module. HS-KAPPA could be helpful in clinical practice and in clinical trials.